Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in EAEU has been experiencing steady growth in recent years.
Customer preferences: Customers in the EAEU region are increasingly looking for anti-hypertensive drugs that are effective, safe, and affordable. They are also interested in drugs that have fewer side effects and are easy to use. In addition, customers are becoming more health-conscious and are taking preventive measures to avoid hypertension.
Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in EAEU is the increasing use of combination therapy. This involves using two or more drugs to treat hypertension, which is more effective than using a single drug. Another trend is the growing popularity of generic drugs, which are cheaper than branded drugs and have the same efficacy and safety profile. Additionally, there is a shift towards using fixed-dose combination drugs, which simplify treatment and improve adherence.
Local special circumstances: The EAEU region comprises five member states, including Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia. Each country has its own unique market conditions, regulatory environment, and healthcare system. For example, Russia has the largest market for anti-hypertensive drugs in the region, due to its large population and high prevalence of hypertension. Belarus has a well-developed pharmaceutical industry and is a major exporter of generic drugs. Kazakhstan has a growing middle class and an increasing burden of non-communicable diseases, including hypertension.
Underlying macroeconomic factors: The Anti-Hypertensive Drugs market in EAEU is influenced by various macroeconomic factors, including population demographics, healthcare expenditure, and government policies. The region has an aging population, which is more prone to hypertension, and a growing burden of non-communicable diseases. Healthcare expenditure is increasing in the region, driven by rising incomes and government initiatives to improve healthcare access and quality. Government policies, such as price controls and reimbursement schemes, also affect the market dynamics. Overall, the Anti-Hypertensive Drugs market in EAEU is expected to continue growing, driven by these underlying macroeconomic factors and customer preferences.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
